Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma
Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors ha...
Saved in:
| Main Authors: | Pandiselvi Ravi, Shyamaladevi Babu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Oral Oncology Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772906024004965 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Transformative advancements in immune checkpoint inhibitor therapy for Oropharyngeal Squamous Cell Carcinoma (OPSCC)
by: Iadalin Ryntathiang, et al.
Published: (2024-09-01) -
Current advances in immunotherapy for cancer
by: Indrajit Desai, et al.
Published: (2024-12-01) -
Pembrolizumab- induced subacute cutaneous lupus erythematosus in a patient with oropharyngeal squamous cell carcinoma: A case report and literature review
by: Beata Mayer, et al.
Published: (2025-12-01) -
An overview of immune checkpoint inhibitor toxicities in bladder cancer
by: Avenie Mavadia, et al.
Published: (2024-12-01) -
The burden and clinical trajectory of immune checkpoint inhibitor-induced endocrinopathies: an 8-year experience
by: Fateen Ata, et al.
Published: (2024-12-01)